| 报告题名: | Thromboprophylactic treatment with rivaroxaban or dabigatran compared with enoxaparin or dalteparin in patients undergoing elective hip- or knee replacement surgery |
| 作者: | Ringerike, Tove; Hamidi, Vida; Hagen, Gunhild; Reikvam, Åsmund; Klemp, Marianne
|
| 出版者: | Norwegian Knowledge Centre for the Health Services
|
| 出版年: | 2011
|
| 发表日期: | 2011-06
|
| 国家: | 挪威
|
| 语种: | 英语
|
| 英文关键词: | VDP::Medisinske Fag: 700
; VDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Ortopedisk kirurgi: 784
; Ortopedi
; Arthroplasty, Replacement, Hip
|
| 中文主题词: | 死亡率
|
| 主题词: | MORTALITY
|
| 英文摘要: | ENGLISH: 1-page key messages
Due to a high risk of thromboembolism in patients undergoing major orthopaedic surgery it has become standard practice to give thromboprophylactic treatment to these patients. Pharmaceutical interventions with or without addition of mechanical methods are recommended.
This project, commissioned by Helse Bergen HF Ortopedisk klinikk, examined thromboprophylaxis with rivaroxaban or dabigatran compared with low-molecular weight heparins (LMWH, i.e. enoxaparin and dalteparin) with regard to efficacy, safety and cost-effectiveness in patients undergoing elective total hip or knee replacement surgery.
We conducted a systematic review of the literature and made cost-effectiveness analyses based on a model that calculated quality-adjusted life years and life time costs.
The main findings were that:
•We did not find statistically significant differences between dabigatran and enoxaparin for mortality, pulmonary embolism, deep vein thrombosis or major bleeding. The quality of the evidence ranged from very low to moderate.
•For rivaroxaban compared with enoxaparin we found statistically a significant reduction in deep vein thrombosis, but also a trend towards increased risk of major bleeding. For mortality and pulmonary embolism there were no statistically significant differences between treatments. The quality of the evidence ranged from very low to moderate.
•Our results indicate a great uncertainty regarding which strategy is the most cost-effective. However, rivaroxaban and enoxaparin had a slightly higher probability of being cost-effective alternatives for patients undergoing total hip or knee replacement, respectively.
•The results of our model analysis of the uncertainty surrounding each group of parameters indicated that more research on efficacy data would have the greatest impact on reducing decision uncertainty. |
| URL: | https://brage.bibsys.no/xmlui/bitstream/handle/11250/2378234/NOKCrapport13_2011.pdf?sequence=1&isAllowed=y
|
| 资源类型: | 研究报告
|
| 标识符: | http://119.78.100.158/handle/2HF3EXSE/28405
|
| Appears in Collections: | 过去全球变化的重建
影响、适应和脆弱性
科学计划与规划
气候变化与战略
全球变化的国际研究计划
气候减缓与适应
气候变化事实与影响
|
| File Name/ File Size |
Content Type |
Version |
Access |
License |
|
|---|
| NOKCrapport13_2011.pdf（825KB） | 研究报告 | -- | 开放获取 | | View
联系获取全文 |
|
| Recommended Citation: | |
Ringerike, Tove,Hamidi, Vida,Hagen, Gunhild,et al. Thromboprophylactic treatment with rivaroxaban or dabigatran compared with enoxaparin or dalteparin in patients undergoing elective hip- or knee replacement surgery. 2011-01-01.
|
|
|